Septerna, Inc. (SEPN)

Septerna, Inc. is a clinical-stage biotechnology company headquartered in South San Francisco, California. It went public on the Nasdaq in 2024 and works on small-molecule drugs aimed at G protein-coupled receptors (GPCRs), a large family of cell-surface receptors involved in many diseases.

Its proprietary Native Complex Platform is designed to isolate GPCRs outside the cell while keeping their natural structure and function. This lets the company run large screening and structure-based design efforts in search of oral drugs for targets that have been hard to reach with conventional methods.

Septerna's pipeline covers endocrinology, immunology and inflammation, and metabolic diseases, including programs related to hypoparathyroidism. It also partners with larger pharmaceutical companies on GPCR drug discovery.